Specificity of polyclonal anti-p53 IgG for isolation of the soluble p53 antigen from human serum

被引:0
|
作者
Sandler, B
Smirnoff, P
Tendelr, Y
Zinder, O
Zusman, R
Zusman, I
机构
[1] Hebrew Univ Jerusalem, Koret Sch Vet Med, Lab Teratol & Expt Oncol, IL-76100 Rehovot, Israel
[2] Hebrew Univ Jerusalem, Fac Agr Food & Environm Qual Sci, Inst Biochem, IL-76100 Rehovot, Israel
[3] Rambam Med Ctr, Dept Clin Biochem, Haifa, Israel
关键词
affinity chromatography; IgG; p53; protein;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The possibility to use anti-p53 IgG for isolation of the soluble p53 antigen as a serological tumor marker has been shown in our previous studies. In order to prove the specificity of such IgG, we compared the effectiveness of columns with anti-p53 IgG and IgG isolated from non-treated rabbits (regular IgG). The gel fiberglass (GFG) columns for affinity chromatography were prepared separately with both types of IgG. The same serum was percolated simultaneously through both columns and the results of elution were compared. The total concentration of tumor-associated antigens (TAA) eluted from the serum of cancer patients was similar in both TAA mixtures isolated either with anti-p53 IgG or with the regular IgG. Differences are manifest in the content of total proteins and amount of each eluted protein: a mixture eluted with the regular IgG contains several proteins whereas the anti-p53 IgG isolated only two proteins, p64 and p53. The amount of the soluble p53 antigen isolated from the cancer serum was significantly higher when it was isolated with anti-p53 IgG. The method developed in our laboratory was shown to be highly specific both to isolate proteins related to cancer (p53) and non-cancer disorders (p64). Data presented in this report show that such specificity can be achieved only if the anti-p53 IgG is used: the regular IgG obtained from non-treated animals isolate many proteins among which the concentration of specific p53 protein is lost.
引用
收藏
页码:767 / 770
页数:4
相关论文
共 50 条
  • [31] Divergence between the high rate of p53 mutations in skin carcinomas and the low prevalence of anti-p53 antibodies
    Moch, C
    Moysan, A
    Lubin, R
    de La Salmonière, P
    Soufir, N
    Galisson, F
    Vilmer, C
    Venutolo, E
    Le Pelletier, F
    Janin, A
    Basset-Séguin, N
    BRITISH JOURNAL OF CANCER, 2001, 85 (12) : 1883 - 1886
  • [32] Divergence between the high rate of p53 mutations in skin carcinomas and the low prevalence of anti-p53 antibodies
    C Moch
    A Moysan
    R Lubin
    P de La Salmonière
    N Soufir
    F Galisson
    C Vilmer
    E Venutolo
    F Le Pelletier
    A Janin
    N Basset-Séguin
    British Journal of Cancer, 2001, 85 : 1883 - 1886
  • [33] The detection of serum anti-p53 antibodies from patients with gastric carcinoma in China
    Qiu, Lin-Lin
    Hua, Pan-Yu
    Ye, Li-Li
    Wang, Yong-Cai
    Qiu, Tian
    Bao, Hui-Zheng
    Wang, Li
    CANCER DETECTION AND PREVENTION, 2007, 31 (01): : 45 - 49
  • [34] Study of p53 gene mutations and serum anti-p53 antibodies in Barrett's esophagus and short segment Barrett's esophagus.
    Vilella, A
    Crespi, S
    Andreu, H
    Ibarra, J
    Garcia, L
    Dolz, C
    GASTROENTEROLOGY, 2000, 118 (04) : A1319 - A1319
  • [35] Restoration of transcriptional activity of p53 mutants in human tumour cells by intracellular expression of anti-p53 single chain Fv fragments
    Claude Caron de Fromentel
    Nadége Gruel
    Corinne Venot
    Laurent Debussche
    Emmanuel Conseiller
    Christine Dureuil
    Jean-Luc Teillaud
    Bruno Tocque
    Laurent Bracco
    Oncogene, 1999, 18 : 551 - 557
  • [36] Restoration of transcriptional activity of p53 mutants in human tumour cells by intracellular expression of anti-p53 single chain Fv fragments
    de Fromentel, CC
    Gruel, N
    Venot, C
    Debussche, L
    Conseiller, E
    Dureuil, C
    Teillaud, JL
    Tocque, B
    Bracco, L
    ONCOGENE, 1999, 18 (02) : 551 - 557
  • [37] Serum levels of pantropic p53 protein and EGF-receptor, and detection of anti-p53 antibodies in former uranium miners (SDAG Wismut)
    Schneider, J
    Presek, P
    Braun, A
    Woitowitz, HJ
    AMERICAN JOURNAL OF INDUSTRIAL MEDICINE, 1999, 36 (06) : 602 - 609
  • [38] HSymM-guided engineering of the immunodominant p53 transactivation domain putative peptide antigen for improved binding to its anti-p53 monoclonal antibody
    Fritz, Zachary R.
    Schloss, Rene S.
    Yarmush, Martin L.
    Williams, Lawrence J.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2021, 51
  • [39] Comparison between a new assay system, Elecsys® Anti-p53, and conventional MESACUP™ for the detection of serum anti-p53 antibodies: A multi-institutional study
    Suzuki, Takashi
    Oshima, Yoko
    Shiratori, Fumiaki
    Nanami, Tatsuki
    Yajima, Satoshi
    Sumazaki, Makoto
    Ushigome, Mitsunori
    Sugita, Hironobu
    Eberl, Magdalena
    Ogata, Hideaki
    Hayashida, Tetsu
    Nakamura, Seigo
    Nakagawa, Tsuyoshi
    Shimada, Hideaki
    MOLECULAR AND CLINICAL ONCOLOGY, 2022, 17 (02)
  • [40] Clinical implication of anti-p53 antibodies and p53-protein in pancreatic disease
    Ohshio, G
    Suwa, H
    Imamura, M
    JOURNAL OF GASTROINTESTINAL CANCER, 2002, 31 (1-3) : 129 - 135